Publication details

Fractional Flow Reserve-Guided PCI or Coronary Bypass Surgery for 3-Vessel Coronary Artery Disease: 3-Year Follow-Up of the FAME 3 Trial

Authors	ZIMMERMANN Frederik M DING Victoria Y PIJLS Nico H J PIROTH Zsolt VAN STRATEN Albert H M SZEKELY Laszlo DAVIDAVICIUS Giedrius KALINAUSKAS Gintaras MANSOUR Samer KHARBANDA Rajesh OSTLUND-PAPADOGEORGOS Nikolaos AMINIAN Adel OLDROYD Keith G AL-ATTAR Nawwar JAGIC Nikola DAMBRINK Jan-Henk E KALA Petr ANGERAS Oskar MACCARTHY Philip WENDLER Olaf CASSELMAN Filip WITT Nils MAVROMATIS Kreton MINER Steven E S SARMA Jaydeep ENGSTROM Thomas CHRISTIANSEN Evald H TONINO Pim A L REARDON Michael J OTSUKI Hisao KOBAYASHI Yuhei HLATKY Mark A MAHAFFEY Kenneth W DESAI Manisha WOO Y Joseph YEUNG Alan C BERNARD De Bruyne FEARON William F
Year of publication	2023
Type	Article in Periodical
Magazine / Source	Circulation
MU Faculty or unit	Faculty of Medicine
Citation
web	https://www.ahajournals.org/doi/10.1161/CIRCULATIONAHA.123.065770
Doi	http://dx.doi.org/10.1161/CIRCULATIONAHA.123.065770
Keywords	coronary artery bypass; drug-eluting stents; percutaneous coronary intervention
Description	BACKGROUND: Previous studies comparing percutaneous coronary intervention (PCI) with coronary artery bypass grafting (CABG) in patients with multivessel coronary disease not involving the left main have shown significantly lower rates of death, myocardial infarction (MI), or stroke after CABG. These studies did not routinely use current-generation drug-eluting stents or fractional flow reserve (FFR) to guide PCI. METHODS: FAME 3 (Fractional Flow Reserve versus Angiography for Multivessel Evaluation) is an investigator-initiated, multicenter, international, randomized trial involving patients with 3-vessel coronary artery disease (not involving the left main coronary artery) in 48 centers worldwide. Patients were randomly assigned to receive FFR-guided PCI using zotarolimus drug-eluting stents or CABG. The prespecified key secondary end point of the trial reported here is the 3-year incidence of the composite of death, MI, or stroke. RESULTS: A total of 1500 patients were randomized to FFR-guided PCI or CABG. Follow-up was achieved in >96% of patients in both groups. There was no difference in the incidence of the composite of death, MI, or stroke after FFR-guided PCI compared with CABG (12.0% versus 9.2%; hazard ratio [HR], 1.3 [95% CI, 0.98-1.83]; P=0.07). The rates of death (4.1% versus 3.9%; HR, 1.0 [95% CI, 0.6-1.7]; P=0.88) and stroke (1.6% versus 2.0%; HR, 0.8 [95% CI, 0.4-1.7]; P=0.56) were not different. MI occurred more frequently after PCI (7.0% versus 4.2%; HR, 1.7 [95% CI, 1.1-2.7]; P=0.02). CONCLUSIONS: At 3-year follow-up, there was no difference in the incidence of the composite of death, MI, or stroke after FFR-guided PCI with current-generation drug-eluting stents compared with CABG. There was a higher incidence of MI after PCI compared with CABG, with no difference in death or stroke. These results provide contemporary data to allow improved shared decision-making between physicians and patients with 3-vessel coronary artery disease. REGISTRATION: URL: https://www.clinicaltrials.gov; Unique identifier: NCT02100722.